Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News BiomX Inc PHGE

Healthcare Biotechnology
BiomX Inc., a clinical-stage biopharmaceutical company, develops phage-based therapies using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases. The company’s phage-based therapies include fixed cocktail therapy, which involves developing a single product containing a fixed number of selected phages to cover a range... see more

Recent & Breaking News (NYSEAM:PHGE)

BiomX Issues Statement Regarding Recent Common Stock Trading Activity

GlobeNewswire January 27, 2026

BiomX Announces $3.0 Million Private Placement

GlobeNewswire December 29, 2025

BiomX Announces Discontinuation of Phase 2b BX004 Trial Following Internal Review

GlobeNewswire December 8, 2025

BiomX Provides Update on BX004 Phase 2b Trial in Cystic Fibrosis

GlobeNewswire November 25, 2025

BiomX Inc. Announces 1-for-19 Reverse Stock Split

GlobeNewswire November 14, 2025

BiomX Reports Third Quarter 2025 Financial Results and Provides Program Updates

GlobeNewswire November 12, 2025

BiomX to Report Third Quarter 2025 Financial Results and Program Updates on November 12, 2025

GlobeNewswire November 5, 2025

BiomX Announces Positive FDA Feedback Supporting Next-Generation Phage Cocktail Program for Diabetic Foot Infections

GlobeNewswire November 4, 2025

BiomX Provides a Program Update and Announces New FDA Feedback Potentially Expanding BX004 Development Pathways

GlobeNewswire October 17, 2025

BiomX CEO to Present at H.C. Wainwright 27th Annual Global Investment Conference

GlobeNewswire September 4, 2025

BiomX Provides Update on BX004 Phase 2b Trial for the Treatment of Patients with Cystic Fibrosis

GlobeNewswire August 19, 2025

BiomX Reports Second Quarter 2025 Financial Results and Provides Program Updates

GlobeNewswire August 13, 2025

BiomX to Report Second Quarter 2025 Financial Results and Program Updates on August 13, 2025

GlobeNewswire August 6, 2025

BiomX Announces Successful Initiation of Phase 2b Trial with First Patient Dosed in BX004 Program in Patients with Cystic Fibrosis

GlobeNewswire July 14, 2025

BiomX Announces Publication in Nature Communications of Phage Cocktail BX004 Phase 1b/2a Part 1 Data Demonstrating Strong Activity in Cystic Fibrosis

GlobeNewswire July 8, 2025

BiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 Conference

GlobeNewswire May 19, 2025

BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates

GlobeNewswire May 15, 2025

BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025

GlobeNewswire May 8, 2025

Crane Harbor Acquisition Corp. Announces Pricing of $200,000,000 Initial Public Offering

GlobeNewswire April 24, 2025

BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure

GlobeNewswire April 1, 2025

Podcasts